Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 23, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Advanced Malignant NeoplasmColorectal Carcinoma Metastatic in the LiverMetastatic Malignant Neoplasm in the LiverRefractory Malignant Neoplasm

Interventions

BIOLOGICAL

Bevacizumab

Given IV

DRUG

Fluorouracil

Given via pump

DRUG

Leucovorin

Given via pump

DRUG

Oxaliplatin

Given via pump

DRUG

Pegylated Liposomal Doxorubicin Hydrochloride

Given IV

DRUG

Temsirolimus

Given IV

PROCEDURE

Tumor Treating Fields Therapy

Use NovoTTF-100L(P) system

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER